These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7353373)

  • 1. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
    Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
    Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
    Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
    Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
    Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
    Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
    Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.
    Muirhead N; Adami S; Sandler LM; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Q J Med; 1982; 51(204):427-44. PubMed ID: 6760236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
    Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D
    Bone; 1992; 13(5):369-77. PubMed ID: 1419378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
    Goldstein DA; Malluche HH; Massry SG
    Contrib Nephrol; 1980; 18():42-54. PubMed ID: 7353379
    [No Abstract]   [Full Text] [Related]  

  • 13. Unique effects of 24,25-dihydroxyvitamin D3 in uremic patients.
    Llach F; Brickman AS; Coburn JW
    Contrib Nephrol; 1980; 18():212-7. PubMed ID: 7353377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between treatment with 1,25(OH)2D3 and glucocorticoids in uremic patients after kidney transplantation.
    Wong EG; Siemsen AW; Sugihara JG; Coburn JW
    Contrib Nephrol; 1980; 18():152-61. PubMed ID: 6986228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL
    Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
    Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA
    Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.